• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Rheumatology Therapeutics Market to 2018 - Increasing Uptake of Benlysta, Uloric, Krystexxa, and the Launch of Oral Tofacitinib to Spur Growth - Product Image

Rheumatology Therapeutics Market to 2018 - Increasing Uptake of Benlysta, Uloric, Krystexxa, and the Launch of Oral Tofacitinib to Spur Growth

  • ID: 2358406
  • December 2012
  • 120 Pages
  • GBI Research

FEATURED COMPANIES

  • Abbott
  • Amgen
  • Janssen Biotech
  • Merck
  • Pfizer
  • MORE

GBI Research, the leading business intelligence provider, has released its latest research, “Rheumatology Therapeutics Market to 2018 - Increasing Uptake of Benlysta, Uloric, Krystexxa, and the Launch of Oral Tofacitinib to Spur Growth”. The report provides insights into the rheumatology therapeutics market forecasts until 2018 and examines global treatment usage patterns for various rheumatology disorders. It also looks at the geographical distribution of the rheumatology disorders therapeutics market across key geographies (the US, the top five countries of Europe, and Japan) and provides insights into the R&D pipeline and promising future blockbusters until 2018. The report also profiles major biopharmaceutical companies in the segment and analyzes M&A activity and licensing agreements.

The reports covers Rheumatoid Arthritis (RA), Osteoarthritis (OA), Systemic Lupus Erythematosus (SLE) and gout, as these are most prevalent forms of rheumatologic disease. The global rheumatology therapeutics market was estimated to be worth $17.1 billion in 2011, having grown at a Compound Annual Growth Rate (CAGR) of 9.4% from 2005, and is forecast to grow at a CAGR of READ MORE >

FEATURED COMPANIES

  • Abbott
  • Amgen
  • Janssen Biotech
  • Merck
  • Pfizer
  • MORE

1.1 List of Tables
1.2 List of Figures

2 Rheumatology Therapeutics Market to 2018 - Introduction
2.1 Introduction

3 Rheumatology Therapeutics Market to 2018 - Market Overview
3.1 Introduction
3.1.1 Revenue
3.1.2 Annual Cost of Treatment
3.1.3 Treatment Usage Pattern

4 Rheumatology Therapeutics Market to 2018 - Geographical Landscape Revenue Analysis by Geography
4.1 The US
4.1.1 Revenue
4.1.2 Annual Cost of Treatment
4.1.3 Treatment Usage Patterns
4.2 Top Five Countries of Europe
4.2.1 Introduction
4.2.2 Revenue
4.2.3 Annual Cost of Treatment
4.2.4 Treatment Usage Patterns
4.3 Japan
4.3.1 Revenue
4.3.2 Annual Cost of Treatment
4.3.3 Treatment Usage Patterns
4.4 Australia
4.4.1 Overview of Rheumatology Market
4.5 China
4.5.1 Revenue
4.6 India
4.6.1 Overview of Rheumatology Market

5 Rheumatology Therapeutics Market to 2018 - Therapeutic Landscape
5.1 Rheumatoid Arthritis Therapeutics Market
5.1.1 Introduction
5.1.2 Revenue
5.1.3 Revenue by Country
5.1.4 Annual Cost of Treatment
5.1.5 Treatment Usage Pattern
5.1.6 Treatment Flow Algorithm
5.1.7 Drivers and Barriers for the Rheumatoid Arthritis Therapeutics Market
5.2 Osteoarthritis Therapeutics Market
5.2.1 Introduction
5.2.2 Revenue
5.2.3 Revenue by Country
5.2.4 Annual Cost of Treatment
5.2.5 Treatment Flow Algorithm
5.2.6 Treatment Usage Pattern
5.2.7 Drivers and Barriers for the Osteoporosis Therapeutics Market
5.3 Gout Therapeutics Market
5.3.1 Introduction
5.3.2 Revenue
5.3.3 Revenue by Country
5.3.4 Annual Cost of Treatment
5.3.5 Treatment Usage Pattern
5.3.6 Treatment Flow Algorithm
5.3.7 Drivers and Barriers for the Gout Therapeutics Market
5.4 Systemic Lupus Erythematosus Therapeutics Market
5.4.1 Introduction
5.4.2 Revenue
5.4.3 Annual Cost of Treatment
5.4.4 Treatment Usage Pattern
5.4.5 Treatment Flow Algorithm
5.4.6 Drivers and Barriers for Systemic Lupus Erythematosus Therapeutics Market

6 Rheumatology Therapeutics Market to 2018 - Pipeline Analysis
6.1 Pipeline Assessment by Clinical Phase of Development
6.2 Key R&D Trends and Future Outlook
6.3 Profiles of Promising Molecules
6.3.1 Tofacitinib
6.3.2 Fostamatinib
6.3.3 LY2127399 (tabalumab)
6.3.4 Naproxcinod
6.3.5 RDEA594 (lesinurad)
6.3.6 BCX4208
6.3.7 Epratuzumab
6.3.8 Lupuzor
6.3.9 Atacicept

7 Rheumatology Therapeutics Market to 2018 - Competitive Landscape
7.1 Abbott
7.1.1 Overview
7.1.2 Major Marketed Products
7.1.3 SWOT Analysis
7.2 Amgen
7.2.1 Overview
7.2.2 Major Marketed Products
7.2.3 SWOT Analysis
7.3 Pfizer
7.3.1 Overview
7.3.2 Major Marketed Products
7.3.3 SWOT Analysis
7.4 Janssen Biotech
7.4.1 Overview
7.4.2 Major Marketed Products
7.4.3 SWOT Analysis
7.5 Merck
7.5.1 Overview
7.5.2 Major Marketed Products
7.5.3 SWOT Analysis

8 Rheumatology Therapeutics Market to 2018 - Strategic Consolidations
8.1 Overview
8.1.1 Deals by Type of Agreement
8.1.2 Deals by Year
8.1.3 Deals by Geography
8.1.4 Profiling of Major Deals

9 Rheumatology Therapeutics Market - Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Bibliography
9.4 Research Methodology
9.4.1 Coverage
9.4.2 Secondary Research
9.4.3 Primary Research
9.5 Therapeutic Landscape
9.5.1 Epidemiology-based Forecasting
9.5.2 Market Size by Geography
9.6 Geographical Landscape
9.7 Pipeline Analysis
9.8 Competitive Landscape
9.8.1 Expert Panel Validation
9.9 Contact Us
9.10 Disclaimer

1.1 List of Tables

Table 1: Rheumatology Therapeutics Market, Global, Revenue ($bn), 2005-2011
Table 2: Rheumatology Therapeutics Market, Global, Revenue Forecasts ($bn), 2011-2018
Table 3: Rheumatology Therapeutics Market, Global, Annual Cost of Therapy ($), 2005-2011
Table 4: Rheumatology Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2018
Table 5: Rheumatology Therapeutics Market, Global, Treatment Usage Patterns (million), 2005-2011
Table 6: Rheumatology Therapeutics Market, Global, Treatment Usage Patterns (million), 2011-2018
Table 7: Rheumatology Therapeutics Market, The US, Revenue ($bn), 2005-2011
Table 8: Rheumatology Therapeutics Market, The US, Revenue Forecasts ($bn), 2011-2018
Table 9: Rheumatology Therapeutics Market, The US, Annual Cost of Therapy ($), 2005-2011
Table 10: Rheumatology Therapeutics Market, The US, Annual Cost of Therapy ($), 2011-2018
Table 11: Rheumatology Therapeutics Market, The US, Treatment Usage Patterns (million), 2005-2011
Table 12: Rheumatology Therapeutics Market, The US, Treatment Usage Patterns (million), 2011-2018
Table 13: Rheumatology Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2005-2011
Table 14: Rheumatology Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2011-2018
Table 15: Rheumatology Therapeutics Market, Top Five Countries of Europe, Revenue ($m), 2005-2011
Table 16: Rheumatology Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2011-2018
Table 17: Rheumatology Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2005-2011
Table 18: Rheumatology Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2011-2018
Table 19: Rheumatology Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (million), 2005-2011
Table 20: Rheumatology Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (million), 2011-2018
Table 21: Rheumatology Therapeutics Market, Japan, Revenue ($bn), 2005-2011
Table 22: Rheumatology Therapeutics Market, Japan, Revenue Forecasts ($bn), 2011-2018
Table 23: Rheumatology Therapeutics Market, Japan, Annual Cost of Therapy ($), 2005-2011
Table 24: Rheumatology Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011-2018
Table 25: Rheumatology Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2005-2011
Table 26: Rheumatology Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2011-2018
Table 27: Rheumatoid Arthritis Therapeutics Market, Global, Revenue ($bn), 2005-2011
Table 28: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2011-2018
Table 29: Rheumatoid Arthritis Therapeutics Market, Global, Revenue by Country ($m), 2005-2011
Table 30: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts by Country ($m), 2011-2018
Table 31: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Therapy ($), 2005-2011
Table 32: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2018
Table 33: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Pattern (million), 2005-2011
Table 34: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Pattern (million), 2011-2018
Table 35: Osteoarthritis Therapeutics Market, Global, Revenue ($bn), 2005-2011
Table 36: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2011-2018
Table 37: Osteoarthritis Therapeutics Market, Global, Revenue ($m), 2005-2011
Table 38: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018
Table 39: Osteoarthritis Therapeutics Market, Global, Annual Cost of Therapy ($), 2005-2011
Table 40: Osteoarthritis Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2018
Table 41: Osteoarthritis Therapeutics Market, Global, Treatment Usage Pattern (millions), 2005-2011
Table 42: Osteoarthritis Therapeutics Market, Global, Treatment Usage Pattern (millions), 2011-2018
Table 43: Gout Therapeutics Market, Global, Revenue ($m), 2005-2011
Table 44: Gout Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018
Table 45: Gout Therapeutics Market, Global, Revenue by Country ($m), 2005-2011
Table 46: Gout Therapeutics Market, Global, Revenue Forecasts by Country ($m), 2011-2018
Table 47: Gout Therapeutics Market, Global, Annual Cost of Therapy ($), 2005-2011
Table 48: Gout Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2018
Table 49: Gout Therapeutics Market, Global, Treatment Usage Pattern (millions), 2005-2011
Table 50: Gout Therapeutics Market, Global, Treatment Usage Pattern (millions), 2011-2018
Table 51: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue ($m), 2005-2011
Table 52: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018
Table 53: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue by Country ($m), 2005-2011
Table 54: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Forecasts by Country ($m), 2011-2018
Table 55: Systemic Lupus Erythematosus Therapeutics Market, Global, Annual Cost of Therapy ($), 2005-2011
Table 56: Systemic Lupus Erythematosus Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2018
Table 57: Systemic Lupus Erythematosus Therapeutics Market, Global, Treatment Usage Pattern (‘000), 2005-2011
Table 58: Systemic Lupus Erythematosus Therapeutics Market, Global, Treatment Usage Pattern (‘000), 2011-2018
Table 59: Rheumatology Therapeutics Market, Global, Deals by Type of Agreement (%), 2007-2012
Table 60: Rheumatology Therapeutics Market, Global, Deals by Geography (%), 2007-2012

1.2 List of Figures

Figure 1: Rheumatology Therapeutics Market, Global, Revenue Forecasts ($bn), 2005-2018
Figure 2: Rheumatology Therapeutics Market, Global, Annual Cost of Therapy ($), 2005-2018
Figure 3: Rheumatology Therapeutics Market, Global, Treatment Usage Patterns (million), 2005-2018
Figure 4: Rheumatology Therapeutics Market, The US, Revenue Forecasts ($bn), 2005-2018
Figure 5: Rheumatology Therapeutics Market, The US, Annual Cost of Therapy ($), 2005-2018
Figure 6: Rheumatology Therapeutics Market, The US, Treatment Usage Patterns (million), 2005-2018
Figure 7: Rheumatology Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2005-2018
Figure 8: Rheumatology Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2005-2018
Figure 9: Rheumatology Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2005-2018
Figure 10: Rheumatology Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (million), 2005-2018
Figure 11: Rheumatology Therapeutics Market, Japan, Revenue Forecasts ($bn), 2005-2018
Figure 12: Rheumatology Therapeutics Market, Japan, Annual Cost of Therapy ($), 2005-2018
Figure 13: Rheumatology Disorders Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2005-2018
Figure 14: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2005-2018
Figure 15: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts by Country ($m), 2005-2018
Figure 16: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Therapy ($), 2005-2018
Figure 17: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Pattern (million), 2005-2018
Figure 18: Rheumatoid Arthritis Therapeutics Market, Rheumatoid Arthritis, Treatment Flow Algorithm
Figure 19: Rheumatoid Arthritis Therapeutics Market, Drivers and Barriers
Figure 20: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2005-2018
Figure 21: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($m), 2005-2018
Figure 22: Osteoarthritis Therapeutics Market, Global, Annual Cost of Therapy ($), 2005-2018
Figure 23: Osteoarthritis Therapeutics Market, Global, Osteoarthritis Pain Treatment Algorithm
Figure 24: Osteoarthritis Therapeutics Market, Global, Treatment Usage Pattern (millions), 2005-2018
Figure 25: Osteoarthritis Therapeutics Market, Global, Drivers and Barriers
Figure 26: Gout Therapeutics Market, Global, Revenue Forecasts ($m), 2005-2018
Figure 27: Gout Therapeutics Market, Global, Revenue Forecasts by Country ($m), 2005-2018
Figure 28: Gout Therapeutics Market, Global, Annual Cost of Therapy ($), 2005-2018
Figure 29: Gout Therapeutics Market, Global, Treatment Usage Pattern (millions), 2005-2018
Figure 30: Gout Therapeutics Market, Treatment Flow Algorithm for Gout
Figure 31: Gout Therapeutics Market, Global, Drivers and Barriers
Figure 32: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Forecasts ($m), 2005-2018
Figure 33: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Forecasts by Country ($m), 2005-2018
Figure 34: Systemic Lupus Erythematosus Therapeutics Market, Global, Annual Cost of Therapy ($), 2005-2018
Figure 35: Systemic Lupus Erythematosus Therapeutics Market, Global, Treatment Usage Pattern (‘000), 2005-2018
Figure 36: Systemic Lupus Erythematosus Therapeutics Market, Treatment Flow Algorithm
Figure 37: Systemic Lupus Erythematosus Therapeutics Market, Global, Drivers and Barriers
Figure 38: Rheumatology Therapeutics Market, Global, Pipeline Molecules by Stage of Development, May, 2012
Figure 39: Rheumatology Therapeutics Market, Abbott, SWOT Analysis
Figure 40: Rheumatology Therapeutics Market, Amgen, SWOT Analysis
Figure 41: Rheumatology Therapeutics Market, Pfizer, SWOT Analysis
Figure 42: Rheumatology Therapeutics Market, Janssen Biotech, SWOT Analysis
Figure 43: Rheumatology Therapeutics Market, Merck, SWOT Analysis
Figure 44: Rheumatology Therapeutics Market, Global, Deals by Type of Agreement (%), 2007-2012
Figure 45: Rheumatology Therapeutics Market, Global, Deals by Year, 2007-2012
Figure 46: Rheumatology Therapeutics Market, Global, Deals by Geography (%), 2007-2012
Figure 47: GBI Research Market Forecasting Model

FEATURED COMPANIES

  • Abbott
  • Amgen
  • Janssen Biotech
  • Merck
  • Pfizer
  • MORE

Biosimilars and Generics to Slow Rheumatology Therapeutics Market Growth

Despite healthy sales of key medications and the positive market impact of an expanding geriatric population, growth in the global rheumatology therapeutics market is expected to slow in the near future due to the entry of biosimilars, states the latest report from healthcare analysts GBI Research.

The new report* predicts the market to climb from a 2011 value of US$17.1 billion to US$23.8 billion by 2018, representing a Compound Annual Growth Rate (CAGR) of 4.8% – almost half of the 2005-2011 CAGR of 9.4%.

GBI Research puts the more modest growth rate down to the expiration of several biologics patents and the emergence of less expensive biosimilar alternatives.

Pfizer’s Celebrex, a major drug in the Osteoarthritis (OA) market, posted sales of US$2.5 billion in the fiscal year ending 2011, showing an increase of 6% from the previous year. Equally, gout treatment Uloric will reach annual revenues of US$890m-US$1.4 billion by 2014, according to producers Teijin Pharma.However, both of these blockbuster drugs will go off patent in 2014, leaving the market open to generic competitors.

In contrast, GBI Research predicts that tofacitinib, a first-in-class oral Disease-Modifying Antirheumatic Drug (DMARD) intended for Rheumatoid Arthritis, will make a positive impact on rheumatology market revenues following its expected debut in 2013.

Due in part to the rise of biosimilars within the market, the Annual Cost of Therapy (ACT) growth rate is expected to fall. During 2005-2011 the average global ACT climbed from US$212 to US$303, at a CAGR of 6.1%, but between the period 2011-2018, the CAGR is expected to drop to a far more modest 1.2%.

*Rheumatology Therapeutics Market to 2018 - Increasing Uptake of Benlysta, Uloric, Krystexxa, and the Launch of Oral Tofacitinib to Spur Growth

This report provides insights into the rheumatology therapeutics market forecasts until 2018 and examines global treatment usage patterns for various rheumatology disorders.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos